IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#688
Positioning
Market Dominance
Services
Healthcare
$25.3B
Adam H. Schechter
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, and prostate-specific antigens. The company also provides specialty testing services, including gene-based and esoteric testing.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = LH ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 17.1% | 10.3% | 35.5% | 14.6% | 10.1% | 105.2% | 0.0% | 41.0x | $244M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.1% | 8.3% | 45.7% | 8.5% | 6.2% | 28.1% | 0.0% | 0.0x | $736M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 0.0% | - | 97.4% | 58.0% | 37.4% | - | 8.8% | 264.0x | $2.5B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 15.3% | 5.8% | 100.0% | 6.9% | 5.2% | 15.1% | 0.0% | 24.0x | $1.8B | VS | |
$LH LABCORP HOLDINGS INC. | 60 | 46 | 63 | 74 | 26.6x | 17.1x | 10.2% | 4.8% | 28.6% | 10.0% | 6.4% | 10.6% | 1.0% | 110.0x | $25.3B | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.7% | 2.4% | 64.6% | 4.5% | 2.8% | 8.6% | 0.0% | 0.3x | - | REF |
LABCORP HOLDINGS INC. (LH) receives a "Hold" rating with a composite score of 60.1/100. It ranks #688 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for LH.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 46 | 49 | -3NEUTRAL |
| MOMENTUM | 74 | 84 | -10DRAG |
| VALUATION | 63 | 71 | -8DRAG |
| INVESTMENT | 42 | 73 | -31DRAG |
| STABILITY | 93 | 99 | -6DRAG |
| SHORT INT | 39 | 31 | +8ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 6.1% vs WACC 8.0% (spread -1.9%)
GM 29% vs sector 65%, OM 10% vs sector 5%
Capital turnover 0.71x
Rev growth 11%, 10yr history
Interest coverage 7.1x, Net debt/EBITDA 12.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate LABCORP HOLDINGS INC. (LH) as a Hold with a composite score of 60.1/100 at a current price of $287.58. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
LABCORP HOLDINGS INC. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 60.1/100 places it at rank #688 in our full universe.
The near-term outlook is constructive, with revenue growing at 11% and momentum in the 74th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
Medium
Poor
Undervalued
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Leverage of 110% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
LABCORP HOLDINGS INC. represents a hold based on multi-factor quantitative performance.
Our model assigns LABCORP HOLDINGS INC. a Hold rating, with a composite score of 60.1/100 and 3 out of 5 stars. Ranked #688 of 7,333 stocks, LH presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 46/100, LH shows adequate but unremarkable business quality. The company reports a return on equity of 10.2% (sector avg: 5.7%), gross margins of 28.6% (sector avg: 64.6%), net margins of 6.4% (sector avg: 2.8%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
LH's value score of 63/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 26.56x, an EV/EBITDA of 17.09x, a P/B ratio of 2.69x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
With an investment score of 42/100, LH exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 10.6% vs. a sector average of 8.6% and a return on assets of 4.8% (sector: 2.4%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
LH shows strong momentum characteristics with a score of 74/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 10.6% year-over-year, while a beta of 0.60 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
LABCORP HOLDINGS INC. earns an excellent stability score of 93/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.60 and a debt-to-equity ratio of 110.00x (sector avg: 0.3x). Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
LABCORP HOLDINGS INC.'s short interest score of 39/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 110.00x). At $25.3B (large-cap), LH carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
LH offers a modest dividend yield of 1.0%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
LABCORP HOLDINGS INC. is a large-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #688 of 7,333 overall (91st percentile). Key comparisons include ROE of 10.2% exceeding the 5.7% sector median and operating margins of 10.0% above the 4.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While LH currently exhibits a HOLD profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Key factor gap
Stability (93) vs Short Int. (39) — closing this gap could shift the rating.
EV/EBITDA 46% ABOVE SECTOR MEDIAN
ROE 77% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 56% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Labcorp’s Q4 results came in below Wall Street’s revenue expectations, leading to a negative market reaction, while management attributed performance to strength in specialty testing and expanded partnerships with hospitals and regional labs. CEO Adam Schechter highlighted the company’s double-digit growth in esoteric testing and the successful integration of recent acquisitions, including Invitae and assets from various health systems. Schechter also acknowledged that lower organic volume growt
AI driven pathology rollout puts Labcorp Holdings (LH) in focus Labcorp Holdings (LH) is back on investors’ radar after expanding its collaboration with PathAI. The companies plan to roll out the FDA cleared AISight Dx digital pathology platform across Labcorp’s national anatomic pathology network. See our latest analysis for Labcorp Holdings. Labcorp’s 1 month share price return of 6.99% and year to date share price return of 13.37% suggest momentum has been building, while the 5 year total...
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology allows pathologists to view and manage slides digitally and use AI to support key steps in the diagnostic process.